Provectus Biopharmaceuticals Launches VisiRose, Provectus's Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in Ophthalmology [Yahoo! Finance]
PROVECTUS BIOPHARMS (PVCT)
NASDAQ:AMEX Investor Relations:
provectusbio.com/financial-overview
Company Research
Source: Yahoo! Finance
the launch of VisiRose, Inc. (“VisiRose”), Provectus's first Founded Entity. This new clinical-stage biotechnology company is focused on commercializing Rose Bengal Photodynamic Antimicrobial Therapy (“RB PDAT”) for the treatment of infectious keratitis and other serious eye infections using Provectus's bioactive synthetic small molecule and active pharmaceutical ingredient (“API”) Rose Bengal Sodium (RBS). The University of Miami (the “University”) is a minority equity shareholder of VisiRose. RB PDAT, a groundbreaking, non-invasive investigational treatment for eye infections, is based on innovative ocular research from the Ophthalmic Biophysics Center at Bascom Palmer Eye Institute (“BPEI”) of the University's Miller School of Medicine. RB PDAT combines a formulation of Provectus's pharmaceutical-grade RBS API and OBC's light-based medical device to treat eye infections caused by bacteria, fungi, and parasites, including multidrug-resistant organisms. Dominic Rodrigues, Acting
Show less
Read more
Impact Snapshot
Event Time:
PVCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PVCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PVCT alerts
High impacting PROVECTUS BIOPHARMS news events
Weekly update
A roundup of the hottest topics
PVCT
News
- Provectus Biopharmaceuticals Launches VisiRose, Provectus’s Founded Entity for Pharmaceutical-grade Rose Bengal Sodium-based Treatments in OphthalmologyGlobeNewswire
- VisiRose Introduces Revolutionary Therapy for Severe Eye Infections [Yahoo! Finance]Yahoo! Finance
- VisiRose Introduces Revolutionary Therapy for Severe Eye InfectionsAccesswire
- Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference CallGlobeNewswire
- Provectus Biopharmaceuticals Announces Fourth Quarter 2024 Conference CallGlobeNewswire
PVCT
Sec Filings
- 12/11/24 - Form 8-K
- 12/6/24 - Form SC
- 12/5/24 - Form 8-K
- PVCT's page on the SEC website